Clinical trials: Sclerosis, Systemic
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Systemic Sclerosis
Individualized Home-based Exercise Program for Patient With Systemic Sclerosis.
Systemic sclerosis (SSc) is an uncommon chronic rheumatic disease with an unknown cause and unpredictable course. The inability, in addition to easy fatigability, starts a vicious circle that leads to a fast deterioration of…
- Trial name
- ESSE2016 (NCT03614208)
- Testing
- Home-care rehabilitation group (HCRG)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Universita di Verona
Systemic Sclerosis, Scleroderma
Scleroderma Registry
Scleroderma is likely caused by a combination of factors, including an external trigger (infection or other exposure) and a genetic predisposition.
- Trial name
- Registry (NCT00074568)
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Systemic Sclerosis (SSc)
A Study of Cizutamig in Systemic Sclerosis
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with SSc.
- Trial name
- NCT07158996
- Testing
- Biological: cizutamig
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Digital Ulcer of Scleroderma
Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers
Digital ulcers are one of the most prevalent complications of scleroderma (systemic sclerosis). There can be found few surveys on effect of topical agents on healing process of the ulcers.
- Trial name
- NCT02801305
- Testing
- Diltiazem Gel 2%, Nitroglycerin Ointment 2%, Vaseline
- Where
- Iran
- Volunteers
- 90 people
- Sponsor
- Mohammad Ali Nazarinia
Systemic Sclerosis
Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease
Systematic sclerosis (SSc) is a potentially severe disease characterized by various visceral involvements including lung. The investigators hypothesize that a respiratory rehabilitation program specifically designed for people…
- Trial name
- SCLERESPIR (NCT05533034)
- Testing
- Rehabilitation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis (SSc), GERD (Gastroesophageal Reflux Disease)
PPI Refractory - GERD Mechanisms in Systemic Sclerosis
The goal of this observational study is to learn about the mechanisms of gastroesophageal reflux disease (GERD) in patients with systemic sclerosis (SSc) who continue to experience reflux symptoms despite treatment with proton…
- Trial name
- NCT07022912
- Testing
- educational healthcare intervention, Objective assessment of GI motility, Evaluation of GERD severity
- Volunteers
- 147 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Early Diffuse Cutaneous Systemic Sclerosis
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
The aim of the study is to compare the effectiveness of commonly used immunosuppressant treatments for early diffuse cutaneous systemic sclerosis (SSc).
- Trial name
- ESOS (NCT02339441)
- Testing
- Methotrexate, Mycophenolate mofetil, Cyclophosphamide
- Volunteers
- 320 people
- Sponsor
- University of Manchester
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Systemic Sclerosis, Face
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
Systemic sclerosis is a rare autoimmune disorder characterized by microangiopathy, activation of the immune system, and sclerosis of tissues including the skin. Facial involvement is frequent and disabling.
- Conditions
- Systemic Sclerosis, Face, Facial Involvement, Rehabilitation
- Trial name
- PREVISS (NCT05177380)
- Testing
- Personalized rehabilitation program of facial involvement in systemic sclerosis, Delivery of a standard prescription for facial rehabilitation
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Strasbourg, France
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
Systemic Sclerosis
Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis
To date, two devices to measure nitric oxide lung diffusing capacity (DLNO) are commercially available in Europe. Previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy…
- Trial name
- NCT05505617
- Testing
- Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- Holger Dressel
Systemic Sclerosis
Color Doppler Ultrasonography Evaluation of Abdominal and Peripheral Vasculopathy in Systemic Sclerosis Patients
In the current study we aim to assess the macrovascular involvement in SSc patients through an ultrasound (US) evaluation of radial and ulnar arteries and splanchnic vessels.
- Trial name
- NCT07012655
- Testing
- Colour Doppler Ultrasound
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Autoimmune Disorders, Systemic Sclerosis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and…
- Conditions
- Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus
- Trial name
- NCT06434363
- Testing
- Tafasitamab, Fludarabine phosphate, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Systemic Sclerosis, Scleroderma
Calcinosis Reduction by Pyrophosphate in SSC
Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory.
- Trial name
- NCT04966416
- Testing
- Pyrophosphate
- Volunteers
- 60 people
- Sponsor
- Szeged University
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
The goal of this clinical trial is to evaluate CLBR001 and SWI019 as a treatment for patients with autoimmune disorders, including systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myositis.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06913608
- Testing
- CLBR001 + SWI019
- Sponsor
- Calibr, a division of Scripps Research
Gastroesophageal Reflux Disease, Systemic Sclerosis
Gastroesophageal Reflux Treatment in Scleroderma
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus…
- Conditions
- Gastroesophageal Reflux Disease, Systemic Sclerosis, Scleroderma
- Trial name
- GERD-SSc (NCT01878526)
- Testing
- Alginic acid, Domperidone
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Khon Kaen University
Lupus Erythematosus, Systemic, Scleroderma, Systemic
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
This research project has the overall objective to investigate the direction of the associations between illness perceptions, their influencing factors and health-related outcomes.
- Trial name
- NCT02655640
- Testing
- Questionnaires
- Volunteers
- 241 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven